Accuray Inc. (ARAY, Financial), a company specializing in radiation oncology solutions, experienced a significant stock movement with a 5.36% increase in its share price. The stock is currently priced at $2.07 per share, with a trading volume of 179,920 shares and a turnover rate of 0.18%. The stock's amplitude stands at 5.56%.
Recent financial reports reveal that Accuray generated $102 million in revenue, with a net loss of $3.95 million. The earnings per share (EPS) are reported at -$0.04, and the gross profit is $34.47 million, reflecting a price-to-earnings (P/E) ratio of -12.15. Currently, there are no institutional ratings recommending a buy, hold, or sell for this stock.
Within the broader medical device industry, which saw an overall increase of 0.40%, several stocks showed notable performance. Dih Holdings Us Inc C/Wts 20/04/2028 (To Pur Com), Movano Inc., and Elutia, Inc. recorded significant gains. Additionally, Spectral Ai, Inc., Nuwellis, Inc., and Sintx Technologies, Inc. were particularly active with high turnover rates of 54.87%, 11.81%, and 10.69% respectively. Stocks with substantial amplitude included Dih Holdings Us Inc C/Wts 20/04/2028 (To Pur Com), Movano Inc., and Nexalin Technology Inc C/Wts (To Pur Com), with amplitudes of 66.66%, 60.91%, and 28.33% respectively.
Accuray Inc. is recognized for its innovative "CyberKnife" technology, which is used to treat various cancers and tumors throughout the body. This system automatically tracks, detects, and corrects for tumor and patient movement in real-time during procedures, allowing for precise, high-dose radiation delivery without manual intervention.
